Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

IOBT

IO Biotech Inc

Apr 26 • 02:11PM ET

1.42

Dollar change -0.03
Percentage change -2.07	%

Healthcare • Biotechnology • Denmark • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.16	Insider Own	37.24%	Shs Outstand	65.88M	Perf Week	-4.05%
Market Cap	93.55M	Forward P/E	-	EPS next Y	-1.30	Insider Trans	-2.58%	Shs Float	41.35M	Perf Month	-17.92%
Income	-86.08M	PEG	-	EPS next Q	-0.36	Inst Own	46.84%	Short Float	0.15%	Perf Quarter	-20.67%
Sales	0.00M	P/S	-	EPS this Y	31.82%	Inst Trans	-0.22%	Short Ratio	0.45	Perf Half Y	47.92%
Book/sh	2.02	P/B	0.70	EPS next Y	3.56%	ROA	-56.91%	Short Interest	0.06M	Perf Year	-24.06%
Cash/sh	2.17	P/C	0.65	EPS next 5Y	-	ROE	-63.29%	52W Range	0.82 - 2.64	Perf YTD	-24.47%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-46.06%	ROI	-63.76%	52W High	-46.21%	Beta	0.56
Dividend TTM	-	Quick Ratio	9.37	Sales past 5Y	0.00%	Gross Margin	-	52W Low	73.96%	ATR (14)	0.11
Dividend Ex-Date	-	Current Ratio	9.37	EPS Y/Y TTM	13.06%	Oper. Margin	0.00%	RSI (14)	34.23	Volatility	7.33% 7.25%
Employees	68	Debt/Eq	0.02	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.33	Target Price	8.00
Option/Short	No / Yes	LT Debt/Eq	0.01	EPS Q/Q	42.94%	Payout	-	Rel Volume	0.41	Prev Close	1.45
Sales Surprise	-	EPS Surprise	-5.82%	Sales Q/Q	-	Earnings	Mar 05 AMC	Avg Volume	136.27K	Price	1.42
SMA20	-9.09%	SMA50	-11.75%	SMA200	-8.42%	Trades		Volume	42,986	Change	-2.07%

Apr-24-24 04:30PM	IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-15-24 08:30AM	IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness (GlobeNewswire)
Apr-09-24 12:00PM	IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103 (GlobeNewswire)
Apr-05-24 08:30AM	IO Biotech Appoints Fai al Miyara, Ph.D., as Chief Business Officer (GlobeNewswire)
08:30AM	IO Biotech Appoints Faical Miyara, Ph.D., as Chief Business Officer (GlobeNewswire)
02:01PM	Loading…
Mar-07-24 02:01PM	IO Biotech Inc (IOBT) Reports Year-End Financial Results and Progress in Clinical Trials (GuruFocus.com) +6.63%
Mar-06-24 04:11PM	IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-05-24 10:52PM	IOBT Stock Earnings: IO Biotech Misses EPS for Q4 2023 (InvestorPlace)
04:40PM	IO Biotech Announces 2023 Fourth-Quarter and Year-End Results (GlobeNewswire)
Feb-26-24 04:05PM	IO Biotech to Present at 44th Annual Cowen Health Care Conference (GlobeNewswire)
Dec-21-23 08:30AM	IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial (GlobeNewswire)
Nov-13-23 08:12AM	IO Biotech Announces 2023 Third Quarter Results (GlobeNewswire)
08:00AM	IO Biotech Appoints Helen Collins, MD, to its Board of Directors (GlobeNewswire)
Nov-10-23 08:00AM	IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma (GlobeNewswire)
Nov-08-23 04:30PM	IO Biotech Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
08:30AM	Loading…
Nov-01-23 08:30AM	IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting (GlobeNewswire)
Oct-24-23 12:30PM	10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis (ACCESSWIRE) +8.38%
Oct-23-23 01:00AM	Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Society for Medical Oncology (ESMO) Congress (GlobeNewswire) -5.05%
Oct-03-23 04:30PM	IO Biotech Announces Three Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting (GlobeNewswire) +10.22%
Sep-12-23 08:05AM	IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer (GlobeNewswire) -13.20%
Sep-06-23 08:35AM	IO Biotech Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Aug-17-23 08:59AM	10 Best New Penny Stocks to Buy Now (Insider Monkey)
Aug-16-23 09:01PM	Stonepine Capital Management, LLC Acquires New Stake in IO Biotech Inc (GuruFocus.com)
Aug-11-23 08:30AM	IO Biotech Announces 2023 Second Quarter Results (GlobeNewswire)
08:05AM	IO Biotech Appoints Heidi Hunter to its Board of Directors (GlobeNewswire)
Aug-08-23 08:05AM	IO Biotech Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023 (GlobeNewswire)
Aug-07-23 08:30AM	IO Biotech, Inc. Announces $75 Million Private Placement Financing (GlobeNewswire)
Jul-28-23 08:05AM	IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial at University of California Davis Comprehensive Cancer Center (GlobeNewswire)
Jul-25-23 04:05PM	IO Biotech Announces Abstract Accepted for Mini Oral Presentation at IASLC 2023 World Conference on Lung Cancer (GlobeNewswire)
Jul-18-23 04:05PM	IO Biotech Strengthens Executive Management and US Presence with Appointment of Qasim Ahmad, MD, as Chief Medical Officer (GlobeNewswire)
09:55AM	Loading…
Jun-15-23 09:55AM	2 Strong Buy Penny Stocks That Could Rally Over 300% (TipRanks) +27.33%
08:18AM	IO Biotech (IOBT) Down Despite Positive Update on Melanoma Study (Zacks)
Jun-14-23 12:42PM	Why Are IO Biotech Shares Trading Lower Today (Benzinga) -26.48%
08:00AM	IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone (GlobeNewswire)
Jun-01-23 08:30AM	IO Biotech Appoints Christine Richter, Ph.D., MBA, as Senior Vice President, Commercial and Program Lead (GlobeNewswire)
May-30-23 04:35PM	IO Biotech to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-11-23 04:05PM	IO Biotech Announces 2023 First-Quarter Results (GlobeNewswire) +9.69%
May-02-23 07:22AM	Is IO Biotech (NASDAQ:IOBT) In A Good Position To Invest In Growth? (Simply Wall St.)
Mar-22-23 06:14AM	The Chief Financial Officer of IO Biotech, Inc. (NASDAQ:IOBT), Amy Sullivan, Just Bought A Few More Shares (Simply Wall St.)
Mar-14-23 04:11PM	IO Biotech Announces 2022 Fourth-Quarter and Year-End Results (GlobeNewswire)
Feb-22-23 07:00AM	IO Biotech to Participate in March 2023 Investor Conferences (GlobeNewswire)
Jan-23-23 08:00AM	IO Biotech Announces Appointment of Devin Smith as General Counsel (GlobeNewswire)
Jan-09-23 07:05AM	IO Biotech Provides Business Update (GlobeNewswire)
Nov-21-22 01:23PM	Analyst Says IO Biotech's Cancer Treatment Approach 'Differentiated' (Benzinga) -12.11%
Nov-09-22 04:07PM	IO Biotech Announces an Invited Oral Presentation and Two Poster Presentations with New Preclinical Data for Additional Pipeline Candidates at the Society for Immunotherapy of Cancers (SITC) 37th Annual Meeting (GlobeNewswire)
04:05PM	IO Biotech Announces Third Quarter Results for 2022 (GlobeNewswire)
Nov-03-22 08:00AM	IO Biotech Announces New Clinical Collaboration with Merck to Evaluate Neoadjuvant and Adjuvant IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) in a Phase 2, Multi-cohort Trial in Patients with Resectable Tumors (GlobeNewswire)
Oct-31-22 08:00AM	IO Biotech to Participate in the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-15-22 08:37AM	Is IO Biotech (NASDAQ:IOBT) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Oct-13-22 04:05PM	IO Biotech Announces Appointment of New Chief Financial Officer (GlobeNewswire)
Oct-05-22 08:05AM	IO Biotech Announces Invited Oral Presentation and Two Poster Presentations at the Society for Immunotherapy of Cancers (SITC) 37th Annual Meeting (GlobeNewswire) -6.98%
Sep-06-22 07:30AM	IO Biotech to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference (GlobeNewswire)
Aug-11-22 05:00PM	IO Biotech Announces Second Quarter Results for 2022 (GlobeNewswire)
Jun-06-22 08:00AM	IO Biotech to Participate in the 2022 BIO International Convention (GlobeNewswire) -6.08%
May-26-22 05:00PM	IO Biotech Announces Two Presentations at the American Society of Clinical Oncology Annual Meeting 2022 (GlobeNewswire)
May-23-22 08:00AM	IO Biotech to Participate in the Jefferies Healthcare Conference (GlobeNewswire)
May-18-22 07:00AM	IO Biotech Announces Initiation of Phase 3 Combination Trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as First-Line Treatment in Advanced Melanoma (GlobeNewswire) -11.00%
May-16-22 04:15PM	IO Biotech Announces First Quarter Results for 2022 (GlobeNewswire) -8.63%
May-08-22 08:07AM	We're Not Very Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Rate (Simply Wall St.)
Apr-22-22 08:33AM	IO Biotech Hosting Key Opinion Leader Webinar Series (GlobeNewswire) +6.62%
Apr-12-22 08:30AM	IO Biotech Announces Initiation of Phase 2 Trial of IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Multi-Arm Basket Trial (GlobeNewswire) -11.69%
Apr-08-22 04:15PM	IO Biotech Announces Presentation of New Data from MM1636 Phase 1/2 Clinical Trial Presented at 2022 AACR Annual Meeting (GlobeNewswire)
Mar-31-22 04:15PM	IO Biotech Announces Year-End Results for 2021 (GlobeNewswire)
Mar-08-22 04:30PM	IO Biotech Announces Acceptance of Abstract to be Presented at AACR Annual Meeting on April 8, 2022 (GlobeNewswire)
Mar-04-22 08:00AM	IO Biotech to Present at 42nd Annual Cowen Healthcare Conference (GlobeNewswire)
Mar-03-22 04:05PM	IO Biotech Announces Appointment of David V. Smith to its Board of Directors (GlobeNewswire) -7.40%
Feb-07-22 07:26AM	What Kind Of Investors Own Most Of IO Biotech, Inc. (NASDAQ:IOBT)? (Simply Wall St.)
Jan-21-22 02:30AM	Nasdaqs European Markets Delivered Record Year in 2021 (GlobeNewswire) -7.04%
Dec-09-21 11:05AM	IO Biotech Announces Publication of Phase 1/2 Melanoma Clinical Trial Results in Nature Medicine (GlobeNewswire)
Dec-06-21 08:00AM	IO Biotech Announces Third Clinical Collaboration with Merck to Evaluate IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Phase 2 Multi-Arm Basket Trial (GlobeNewswire) -6.88%
Dec-02-21 03:04PM	Morgan Stanley Predicts Over 100% Rally for These New Strong Buy Stocks (TipRanks) +7.40%
Nov-11-21 08:43AM	4 Stocks Insiders Are Buying (Benzinga)
Nov-09-21 11:06AM	IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Nov-05-21 05:06PM	Real Good Food and 3 More Companies Went Public Friday. Heres How They Did. (Barrons.com)
Nov-04-21 11:52PM	IO Biotech, Inc. Announces Pricing of Initial Public Offering (GlobeNewswire)

IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. Its platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. The company was founded by Mai-Britt Zocca, Inge Marie Svane, and Mads Hald Andersen in December 2014 and is headquartered in Copenhagen, Denmark.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Novo Holdings A/S	10% Owner	Feb 09 '24	Sale	1.50	658,809	988,411	5,088,258	Feb 13 09:31 PM
Burkavage Brian	Chief Accounting Officer	Nov 22 '23	Buy	1.03	5,000	5,175	11,500	Nov 24 05:37 PM
Burkavage Brian	Chief Accounting Officer	Nov 21 '23	Buy	0.99	5,000	4,950	6,500	Nov 24 05:37 PM
Vivo Capital IX, LLC	10% Owner	Aug 09 '23	Buy	1.90	3,157,894	5,999,999	3,157,894	Aug 10 09:03 AM
Novo Holdings A/S	10% Owner	Aug 09 '23	Buy	2.02	2,469,135	4,999,998	5,707,467	Aug 11 04:31 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IOBT

IO Biotech Inc

Upgrade your FINVIZ experience